CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:
Net product sales	$ 448,844	$ 367,118	$ 1,229,244	$ 1,019,751
Sanofi collaboration revenue	132,925	134,359	406,028	319,161
Bayer HealthCare collaboration revenue	135,853	88,583	358,460	134,594
Technology licensing and other revenue	8,166	6,967	23,496	20,827
Total revenues	725,788	597,027	2,017,228	1,494,333
Expenses:
Research and development	337,728	224,045	919,608	591,807
Selling, general, and administrative	149,748	97,607	361,012	247,330
Cost of goods sold	33,655	28,253	91,073	83,557
Cost of collaboration manufacturing	21,938	10,320	54,471	23,684
Total expenses	543,069	360,225	1,426,164	946,378
Income from operations	182,719	236,802	591,064	547,955
Other income (expense):
Investment and other income	2,591	618	5,205	2,028
Interest expense	(9,232)	(11,736)	(31,022)	(34,776)
Loss on extinguishment of debt	0	0	(10,787)	0
Total other income (expense)	(6,641)	(11,118)	(36,604)	(32,748)
Income before income taxes	176,078	225,684	554,460	515,207
Income tax expense	(96,358)	(84,378)	(316,562)	(187,651)
Net income	79,720	141,306	237,898	327,556
Net income per share - basic	$ 0.79	$ 1.44	$ 2.37	$ 3.36
Net income per share - diluted	$ 0.70	$ 1.25	$ 2.10	$ 2.95
Weighted average shares outstanding - basic	100,796	98,226	100,325	97,602
Weighted average shares outstanding - diluted	117,423	116,713	113,203	115,554
Statements of Comprehensive Income
Net income	79,720	141,306	237,898	327,556
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax	22,632	578	28,083	(1,685)
Comprehensive income	$ 102,352	$ 141,884	$ 265,981	$ 325,871